Table 1 Pathological and clinical status of mammary carcinomas in female dogs
Parameters | Total (n = 51) | MC-BMT (n = 31) | MC (n = 20) |
|---|---|---|---|
Lymph node metastasis | 43.0% (22/51) | 39.0% (12/31) | 50.0% (10/20) |
Pulmonary metastasis | 13.7% (07/51) | 9.7% (03/31) | 20.0% (04/20) |
Histologic grade | |||
Grade I | 58.8% (30/51) | 80.6% (25/31) | 25.0% (05/20) |
Grade II | 29.4% (15/51) | 19.0% (06/31) | 45.0% (09/20) |
Grade III | 11.8% (06/51) | 0.0% (0/31) | 30.0% (06/20) |
Size | |||
3-5 cm | 35.3% (18/51) | 35.5% (11/31) | 35.0% (07/20) |
>5 cm | 64.7% (33/51) | 64.5% (20/31) | 65.0% (13/20) |
Clinical Staging | |||
Stage II | 29.4% (15/51) | 29.0% (09/31) | 30.0% (06/20) |
Stage III | 25.5% (13/51) | 29.0% (09/31) | 20.0% (04/20) |
Stage IV | 29.4% (15/51) | 38.7% (12/31) | 15.0% (03/20) |
Stage V | 15.7% (08/51) | 3.2% (01/31)* | 35.0% (07/20) |